Filing Analysis
At its 2026 Annual Meeting on June 8, 2026, MetaVia Inc. stockholders approved a reverse stock split in a range of 1-for-5 to 1-for-22. The filing also confirms the election of two directors, the ratification of BDO USA, P.C. as auditors, and an increase of 200,000 shares to the 2022 Equity Incentive Plan.
🚩 Red Flags
- Approval of a reverse stock split is a major red flag for micro-cap companies, typically indicating a struggle to maintain minimum bid price requirements for Nasdaq listing.
- Multiple 8-K items (5.02, 5.07, 9.01) reported in a single filing.
- The reverse split ratio is wide (1-for-5 to 1-for-22), providing the board significant discretion to aggressively reduce share count.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio between 1-for-5 and 1-for-22, to be determined by the Board of Directors.
- The 2022 Equity Incentive Plan was amended to increase the pool of issuable common stock by 200,000 shares.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- D. Gordon Strickland and James P. Tursi, M.D. were elected as Class I directors for three-year terms.
- A quorum was established with 2,866,545 shares present and entitled to vote.
MetaVia Inc. announced the presentation of late-breaking clinical and preclinical data for its obesity and metabolic disease portfolio at the 2026 American Diabetes Association (ADA) Scientific Sessions. The data focuses on the Phase 1 results for DA-1726 and preclinical combination studies for vanoglipel.
📋 Key Facts
- DA-1726 (GLP1R/GCGR dual agonist) Phase 1 results showed a 9.1% reduction in body weight at Day 54 (p<0.05 vs placebo).
- DA-1726 demonstrated a reduction in waist circumference of 9.8 cm at Day 54.
- Vanoglipel (GPR119 agonist) in combination with resmetirom showed a 23.6% weight reduction in MASH mouse models (p<0.05).
- Vanoglipel in combination with metformin showed a 16.3% weight reduction versus control in hyperglycemic mouse models (p<0.05).
- DA-1726 was reported as generally well tolerated with mild-to-moderate gastrointestinal adverse events.
MetaVia Inc. announced the presentation of new Phase 1 data for its drug candidate DA-1726 (a dual GLP1R and GCGR agonist) at the European Association for the Study of the Liver Congress 2026 (EASL 2026) in Barcelona, Spain.
📋 Key Facts
- The announcement was made via a press release dated May 27, 2026.
- The data pertains to Phase 1 clinical trials of DA-1726.
- DA-1726 is a dual oxyntomodulin (OXM) analog agonist targeting GLP1R and GCGR.
- The presentation is part of a late-breaking poster presentation at EASL 2026 (May 27-30, 2026).
MetaVia Inc. announced that three late-breaking abstracts for its cardiometabolic drug candidates, DA-1726 and vanoglipel (DA-1241), have been accepted for poster presentations at the American Diabetes Association’s (ADA) 2026 Scientific Sessions.
📋 Key Facts
- The ADA 2026 Scientific Sessions will be held June 5-8, 2026, in New Orleans.
- DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting GLP-1 and glucagon receptors for obesity treatment.
- Vanoglipel (DA-1241) is a novel G-protein-coupled receptor 119 (GPR119) agonist.
- Three late-breaking abstracts were accepted for presentation.
- The information was furnished under Item 7.01 and is not deemed 'filed' for regulatory purposes.
MetaVia Inc. announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The filing includes a press release and an updated corporate presentation intended for investor communications.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- Updated corporate presentation released on May 14, 2026.
- Press release furnished as Exhibit 99.1.
- Corporate presentation furnished as Exhibit 99.2.
MetaVia Inc. announced that a late-breaking abstract for its obesity drug candidate, DA-1726, has been accepted for a poster presentation at the EASL Congress 2026. The presentation will highlight the dual oxyntomodulin analog's mechanism targeting GLP-1 and glucagon receptors.
📋 Key Facts
- Late-breaking abstract for DA-1726 accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026.
- DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting GLP-1 and glucagon receptors for obesity treatment.
- The EASL Congress 2026 is scheduled to take place May 27–30, 2026, in Barcelona, Spain.
- The disclosure was made under Item 7.01 (Regulation FD), which is typically furnished rather than filed.
MetaVia Inc. announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a dual GLP-1 and glucagon receptor analog. This stage of the study will utilize 16-week titration cohorts to evaluate dose-escalation strategies and optimize patient tolerability.
📋 Key Facts
- First patient dosed in Part 3 of Phase 1 clinical trial for DA-1726 on April 10, 2026.
- DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors.
- Part 3 consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies.
- The primary goal of this phase is to safely achieve higher target doses and optimize tolerability.
MetaVia Inc. filed a Form 8-K to furnish an updated corporate presentation for March 2026. The presentation is intended for use in upcoming investor communications and conferences.
📋 Key Facts
- The filing was made on March 26, 2026, under Item 7.01 (Regulation FD Disclosure).
- An updated corporate presentation was posted to the company's investor relations website.
- The presentation is included as Exhibit 99.1 to the filing.
- The information provided is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
MetaVia Inc. reported its financial results for the fiscal year ended December 31, 2025, and provided a corporate update. The announcement was made via a press release on March 26, 2026, and furnished under Item 2.02.
📋 Key Facts
- Announced financial results for the year ended December 31, 2025
- Provided a corporate update alongside financial results
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- CEO Hyung Heon Kim signed the filing
MetaVia Inc. announced that it has received Institutional Review Board (IRB) approval to commence Phase 1 Part 3 of its clinical trial for DA-1726, a dual GLP-1 and glucagon receptor agonist. The trial will evaluate safety and efficacy in 40 obese subjects, with initial dosing expected in April 2026 and data results anticipated in Q4 2026.
📋 Key Facts
- IRB approval obtained from Clinical Pharmacology of Miami for Phase 1 Part 3 of DA-1726.
- DA-1726 is a novel, dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors.
- The trial will enroll 40 obese, otherwise healthy adult subjects randomized 4:1 (active vs. placebo).
- Part 3A evaluates a one-step titration to 48 mg; Part 3B evaluates a two-step titration to 64 mg.
- Initial dosing is scheduled for April 2026.
- Top-line data readout is expected in the fourth quarter of 2026.